A randomised trial to evaluate whether treatment can be reduced without compromising effficacy in a low risk group of patients defined by a molecular minimal residual disease (MRD) technique; and to evaluate whether further post-remission intensification can improve outcome for a MRD-defined high risk group.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Mercaptopurine; Methotrexate; Methotrexate; Pegaspargase; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 10 Dec 2012 Results for high risk patients presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
- 09 Nov 2011 UKCRN reports status as active, no longer recruiting, and planned end date as 30 June 2011.
- 02 Nov 2011 United Kingdom Clinical Research Network reports accrual to date changed from 151% to 152%.